TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29485525

Group type: EXPERIMENTAL
Intervention: Pulmonary Rehabilitation (PR) program for 3 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no PR program)
Number of subjects: 40
Study: 27469242

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 31
Study: 24262772

Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR)
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Paper Questionnaire (PQ)
Number of subjects: 923

Group type: EXPERIMENTAL
Intervention: Personal Digital Assistant (PDA)
Number of subjects: 923

Group type: COMPARATOR
Intervention: Personal Computer (PC)
Number of subjects: 923
Study: 22536592

Group type: EXPERIMENTAL
Intervention: Lycopene gel
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study: 19886920

Group type: EXPERIMENTAL
Intervention: Grass allergy immunotherapy tablet (AIT) - Graza (Phleum pratense 75,000 SQ‐T/2800 BAU; ALK, Denmark) for 3 years followed by 1 year follow-up
Number of subjects: 283

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Grass allergy immunotherapy tablet (AIT) - Graza
Number of subjects: 283
Study: 18165645

Group type: EXPERIMENTAL
Intervention: Radical Prostatectomy plus Adjuvant Radiation Therapy (RP+RT)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Radical Prostatectomy alone (RP)
Number of subjects: 217
Study: 17998695

Group type: EXPERIMENTAL
Intervention: Trastuzumab (Herceptin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant setting trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 0
Study: 12951650

Group type: EXPERIMENTAL
Intervention: Intranasal insulin (60 IU, once daily)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10731776

Group type: EXPERIMENTAL
Intervention: Affective pictures (pleasant and unpleasant) presented in a random order with a faster presentation rate (1.5 s)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Affective pictures of high arousal
Number of subjects: 0

Group type: COMPARATOR
Intervention: Neutral pictures
Number of subjects: 0
Study: 8964890

Group type: EXPERIMENTAL
Intervention: 0.5 mg DEX daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 1390330

Group type: EXPERIMENTAL
Intervention: Captopril (mean daily dosage 56 +/- 5 mg)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Enalapril (mean daily dosage 9.5 +/- 0.4 mg)
Number of subjects: 29
Study: 3924981

Group type: EXPERIMENTAL
Intervention: Pseudomonic acid cream applied three times a day for 5 days
Number of subjects: 68
Study: 30275428

Group type: EXPERIMENTAL
Intervention: Physical exercise program with Spirulina maxima (SE)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Physical exercise program without Spirulina maxima (Ex)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: No-exercise program with Spirulina maxima (Sm)
Number of subjects: 52

Group type: COMPARATOR
Intervention: No-exercise program without Spirulina maxima (C)
Number of subjects: 52
Study: 28264725

Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy (ESWT) using PiezoWave 2 shockwave system, administered three times per week for 3 weeks.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham treatment to the calf muscle bulk, administered three times per week for 3 weeks.
Number of subjects: 0
Study: 25243340

Group type: EXPERIMENTAL
Intervention: EP-101 (12.5-400 μg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 24257398

Group type: EXPERIMENTAL
Intervention: Continuous interscalene brachial plexus block (CISB) with 20 mL of 0.5% ropivacaine as a bolus and infusion of 0.2% ropivacaine at 5 mL/h for 48 hours
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Single injection interscalene block (SISB) with 20 mL of 0.5% ropivacaine
Number of subjects: 71

Group type: COMPARATOR
Intervention: General anesthesia (GA)
Number of subjects: 71
Study: 20920825

Group type: EXPERIMENTAL
Intervention: Ranibizumab
Number of subjects: 0
Study: 18491170

Group type: EXPERIMENTAL
Intervention: OGTT performed before discharge
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: OGTT performed 3 months after discharge
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Multivariate regression analysis
Number of subjects: 96
Study: 16126809

Group type: EXPERIMENTAL
Intervention: Vitamin C (800 mg/day for 4 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12545257

Group type: EXPERIMENTAL
Intervention: 5 mg morphine sulfate
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: 10 ml 0.25% ropivacaine
Number of subjects: 113

Group type: COMPARATOR
Intervention: Physiological NaCl solution (placebo)
Number of subjects: 113
Study: 10691067

Group type: EXPERIMENTAL
Intervention: Esmarch bandage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Arm elevation/arterial compression (AE/AC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pneumatic vinyl splint
Number of subjects: 0
Study: 9506001

Group type: EXPERIMENTAL
Intervention: Azelastine HCl (4.4 mg every 12 hrs)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Azelastine with ketoconazole (200 mg every 12 hrs)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ketoconazole alone (after a 21-day washout period)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (in the azelastine/placebo group)
Number of subjects: 12
Study: 8476215

Group type: EXPERIMENTAL
Intervention: OK-432 intracutaneous injection
Number of subjects: 0
Study: 3533699

Group type: EXPERIMENTAL
Intervention: Chlorambucil (0.5-4 mg/day)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control (no therapy)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Chlorambucil
Number of subjects: 24
Study: 30126672

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg) + Desmopressin (40 micrograms, 4 puffs)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Indomethacin (100 mg) + Placebo
Number of subjects: 124
Study: 27890487

Group type: EXPERIMENTAL
Intervention: High polyphenol intake (upper tertile)
Number of subjects: 2573

Group type: COMPARATOR
Intervention: Low polyphenol intake (lower tertile)
Number of subjects: 2573
Study: 25343570

Group type: EXPERIMENTAL
Intervention: Subglottic secretion suctioning
Number of subjects: 352

Group type: COMPARATOR
Intervention: No subglottic secretion suctioning (control)
Number of subjects: 352
Study: 23290819

Group type: EXPERIMENTAL
Intervention: PPM plus cisplatin (230 mg/m(2) + 60 mg/m(2))
Number of subjects: 276

Group type: COMPARATOR
Intervention: Paclitaxel plus cisplatin (175 mg/m(2) + 60 mg/m(2))
Number of subjects: 276
Study: 21069291

Group type: EXPERIMENTAL
Intervention: 2 days urinary catheterization
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 3 days urinary catheterization
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 4 days urinary catheterization
Number of subjects: 90
Study: 19920718

Group type: EXPERIMENTAL
Intervention: tDCS/TENS
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: tDCS
Number of subjects: 8

Group type: COMPARATOR
Intervention: sham
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: tDCS/TENS vs tDCS
Number of subjects: 8
Study: 16989957

Group type: EXPERIMENTAL
Intervention: Community Reinforcement Approach (CRA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 0
Study: 14755810

Group type: EXPERIMENTAL
Intervention: Direct Stenting (DS)
Number of subjects: 910

Group type: COMPARATOR
Intervention: Conventional Stenting (CS)
Number of subjects: 910
Study: 11207081

Group type: EXPERIMENTAL
Intervention: Asymptomatic patients with left ventricular ejection fraction <25%
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Symptomatic patients with left ventricular ejection fraction <25%
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 9

Group type: COMPARATOR
Intervention: Asymptomatic patients
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Symptomatic patients
Number of subjects: 9
Study: 9633342

Group type: EXPERIMENTAL
Intervention: Capnography monitoring during weaning from mechanical ventilation
Number of subjects: 0
Study: 7877883

Group type: EXPERIMENTAL
Intervention: Untreated cystinotic children (n=9)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cystinotic children treated with cysteamine
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Cystinotic children after abrogation of cysteamine treatment for 3 or 4 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control children (n=8)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Normal adults (n=25)
Number of subjects: 9
Study: 3278170

Group type: EXPERIMENTAL
Intervention: epsilon‐aminocaproic acid
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 29851267

Group type: EXPERIMENTAL
Intervention: ANACONDA with simple presetting parameters
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ANACONDA with detailed presetting parameters
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MORFEUS with simple presetting parameters
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MORFEUS with detailed presetting parameters
Number of subjects: 10
Study: 28455473

Group type: EXPERIMENTAL
Intervention: Kinematically aligned TKA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mechanically aligned TKA
Number of subjects: 60
Study: 26113503

Group type: EXPERIMENTAL
Intervention: 0.2 μg/day fluocinolone acetonide (FAc) implant in cataract after implant (CAI) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2 μg/day fluocinolone acetonide (FAc) implant in cataract before implant (CBI) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.2 μg/day fluocinolone acetonide (FAc) implant
Number of subjects: 0
Study: 23123504

Group type: EXPERIMENTAL
Intervention: LOW (10 rpm)
Number of subjects: 8

Group type: COMPARATOR
Intervention: HIGH (50 rpm)
Number of subjects: 8
Study: 21113799

Group type: EXPERIMENTAL
Intervention: Treatment of co-morbid drug abuse
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Past adolescent conduct disorder, being younger and male, symptoms of Akathisia, and drug abuse
Number of subjects: 0
Study: 18664707

Group type: EXPERIMENTAL
Intervention: Word Identification (WI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Magnitude Estimation Scaling (MES)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Word Identification (WI) and Magnitude Estimation Scaling (MES)
Number of subjects: 0
Study: 16556697

Group type: EXPERIMENTAL
Intervention: Prone ventilation for 20 h/d
Number of subjects: 136

Group type: COMPARATOR
Intervention: Supine ventilation
Number of subjects: 136
Study: 12728089

Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanate (45 mg/kg/d) for 7 days
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 66
Study: 11085693

Group type: EXPERIMENTAL
Intervention: Stapled haemorrhoidectomy
Number of subjects: 22
Study: 8976822

Group type: EXPERIMENTAL
Intervention: Carboplatin 500 mg/m2 plus two doses of amifostine 910 mg/m2/dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Carboplatin 500 mg/m2
Number of subjects: 0
Study: 1546776

Group type: EXPERIMENTAL
Intervention: AIDS education
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: AIDS education with optional HIV antibody testing
Number of subjects: 313

Group type: COMPARATOR
Intervention: Wait list
Number of subjects: 313
Study: 6208387

Group type: EXPERIMENTAL
Intervention: D-40 (5 units administered at 75 to 100 ml/hr, two during and immediately after operation, one each 3 days postoperatively)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control (no D-40 administered)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: D-40
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control
Number of subjects: 156
Study: 27381981

Group type: EXPERIMENTAL
Intervention: Bouncer friendliness (unfriendly)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Room temperature (hot)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Patron sex composition (majority male)
Number of subjects: 681

Group type: EXPERIMENTAL
Intervention: Fight participants
Number of subjects: 681

Group type: COMPARATOR
Intervention: Non-participants
Number of subjects: 681
Study: 30285894

Group type: EXPERIMENTAL
Intervention: Anakinra
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 26724311

Group type: EXPERIMENTAL
Intervention: Recruitment strategies including direct mailers, phone calls, in-person meetings, and hiring community members
Number of subjects: 31
Study: 25306750

Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day in combination with metformin 2 g/day
Number of subjects: 82

Group type: COMPARATOR
Intervention: Metformin 1.5-2 g/day
Number of subjects: 82
Study: 19640353

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide 600 - 6,000 microg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15805377

Group type: EXPERIMENTAL
Intervention: Naloxone hydrochloride 0.01 mg/kg administered intravenously before oral administration of 1 mL of 30% glucose
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (saline solution) administered intravenously before oral administration of glucose
Number of subjects: 30
Study: 11207036

Group type: EXPERIMENTAL
Intervention: OK-432 intratumoral injection (10 KE) before surgery
Number of subjects: 370

Group type: COMPARATOR
Intervention: Control group (no OK-432 injection)
Number of subjects: 370
Study: 9562618

Group type: EXPERIMENTAL
Intervention: Heparin during hemodialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous administration of heparin in normal controls
Number of subjects: 0
Study: 8056701

Group type: EXPERIMENTAL
Intervention: Gentamicin 4 mg/kg once daily i.v.
Number of subjects: 126

Group type: COMPARATOR
Intervention: Netilmicin 5.5 mg/kg once daily i.v.
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Gentamicin 4 mg/kg once daily i.v. (treated > or = 48 hours)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Netilmicin 5.5 mg/kg once daily i.v. (treated > or = 48 hours)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Gentamicin and Netilmicin
Number of subjects: 126
Study: 2973215

Group type: EXPERIMENTAL
Intervention: Patients with LV hypertrophy
Number of subjects: 544

Group type: COMPARATOR
Intervention: Patients without LV hypertrophy
Number of subjects: 544
Study: 12500513

Group type: EXPERIMENTAL
Intervention: Methylene blue 0.5 mg.kg‐1.h‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (isotonic saline)
Number of subjects: 30
Study: 30502851

Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose (FCM) - 1000mg IV infusion over 15 minutes
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: Iron Polymaltose (IPM) - 1000mg IV infusion over 2 hours
Number of subjects: 246

Group type: COMPARATOR
Intervention: Oral Ferrous Sulphate - 325mg daily until delivery
Number of subjects: 246
Study: 27513339

Group type: EXPERIMENTAL
Intervention: Protandim® (1 pill a day for 90 days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (for 90 days)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Protandim® (in subgroup ≥ 35 years)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (in subgroup ≥ 35 years)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Protandim®
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Protandim® and Placebo
Number of subjects: 38
Study: 24344222

Group type: EXPERIMENTAL
Intervention: Web‐based self-report assessment and educational intervention (screening, targeted education, communication coaching, tracking/graphing SxQOL)
Number of subjects: 752

Group type: COMPARATOR
Intervention: Control group (SxQOL screening at four time points)
Number of subjects: 752

Group type: EXPERIMENTAL
Intervention: Intervention group (Web‐based self-care support and communication coaching)
Number of subjects: 752
Study: 22390464

Group type: EXPERIMENTAL
Intervention: Passive reading of food words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive reading of tool words
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Passive reading of object-related nouns
Number of subjects: 0
Study: 19800983

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg daily
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Atorvastatin (both doses)
Number of subjects: 185
Study: 18381786

Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 104
Study: 15943653

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Sertraline (SRT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Combined treatment of CBT and SRT (COMBINED)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Individual counselling
Number of subjects: 38
Study: 12610822

Group type: EXPERIMENTAL
Intervention: 2.5 g lidocaine/prilocaine cream applied to the injection site 60-90 min before the procedure
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo cream applied to the injection site 60-90 min before the procedure
Number of subjects: 31
Study: 10589886

Group type: EXPERIMENTAL
Intervention: Weekly sulfadoxine/pyrimethamine
Number of subjects: 120

Group type: COMPARATOR
Intervention: Daily trimethoprim-sulfamethoxazole
Number of subjects: 120
Study: 8694609

Group type: EXPERIMENTAL
Intervention: Antegrade cardioplegia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Combined route of delivery (initially antegrade followed by retrograde)
Number of subjects: 60
Study: 1746416

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 170
Study: 7110969

Group type: EXPERIMENTAL
Intervention: 5 mg/h Risordan intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 mg/h Risordan intravenously
Number of subjects: 12
Study: 31345172

Group type: EXPERIMENTAL
Intervention: Joint models analysis
Number of subjects: 0
Study: 30107843

Group type: EXPERIMENTAL
Intervention: Our Choice intervention with enhanced training and supervision (SCC1)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Our Choice intervention implemented by the Ministry of Health's standard approach (SCC2)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Usual care (existing FP services)
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: SCC1 and SCC2
Number of subjects: 360

Group type: COMPARATOR
Intervention: SCC1, SCC2, and usual care
Number of subjects: 360
Study: 27822031

Group type: EXPERIMENTAL
Intervention: Respiratory muscle stretching combined with aerobic training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (upper and lower limb muscle stretching)
Number of subjects: 30
Study: 24937476

Group type: EXPERIMENTAL
Intervention: Inhaled IFN‐β (n = 72)
Number of subjects: 147

Group type: COMPARATOR
Intervention: Placebo (n = 75)
Number of subjects: 147
Study: 22578914

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg) 0.5 g/kg per day for 4 consecutive days, given every month for 6 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone 0.5 g in 250 mL sodium chloride solution per day for 4 consecutive days, given every month for 6 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intravenous methylprednisolone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIg)
Number of subjects: 45
Study: 21302708

Group type: EXPERIMENTAL
Intervention: Refractive lens exchange with multifocal intraocular lens implantation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: LASIK monovision
Number of subjects: 100
Study: 17548840

Group type: EXPERIMENTAL
Intervention: Capecitabine plus oxaliplatin (CAPOX)
Number of subjects: 474

Group type: COMPARATOR
Intervention: Infusional fluorouracil (FU)/folinic acid plus oxaliplatin (FUFOX)
Number of subjects: 474
Study: 15866398

Group type: EXPERIMENTAL
Intervention: Topical betamethasone 0.1% cream
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 56
Study: 11956506

Group type: EXPERIMENTAL
Intervention: SB 249417 (humanized anti-factor IX antibody)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 26
Study: 9457933

Group type: EXPERIMENTAL
Intervention: Transdermal E2 (100 microg/d)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 28
Study: 7620000

Group type: EXPERIMENTAL
Intervention: Intravenous immune globulin (IVIG; 750 mg/kg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: IVIG with neutralization titer of > or = 1:800 to the patients' own viral isolates
Number of subjects: 16
Study: 2794183

Group type: EXPERIMENTAL
Intervention: Immediate group parent training program
Number of subjects: 46

Group type: COMPARATOR
Intervention: Delayed group parent training program
Number of subjects: 46
Study: 22381

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lorazepam (4 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (1-2 mg)
Number of subjects: 0
Study: 31291683

Group type: EXPERIMENTAL
Intervention: WhiteTeeth mobile app + usual care (n = 67)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care only (n = 65)
Number of subjects: 132
Study: 31148979

Group type: EXPERIMENTAL
Intervention: 600µg of rectal misoprostol
Number of subjects: 122

Group type: COMPARATOR
Intervention: 20IU of oxytocin infusion
Number of subjects: 122
Study: 29144240

Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Oral sucrose
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combination therapy (music + sucrose)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Combination therapy
Number of subjects: 35
Study: 25990055

Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium 1 mg/d for 8 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium 2 mg/d for 8 weeks
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Pitavastatin calcium (both doses)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 40